Sandoz Group (SDZNY) News Today → Charles Payne Demystifies Options (From Unstoppable Prosperity) (Ad) Free SDZNY Stock Alerts $35.77 +0.48 (+1.36%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 10:02 PM | reuters.comEx-Sandoz exec gets probation for price-fixing after cooperation dealMay 11, 2024 | americanbankingnews.comSandoz Group AG (OTCMKTS:SDZNY) Sees Significant Decrease in Short InterestMay 7, 2024 | markets.businessinsider.comBiosimilars Boosts Sandoz Q1 Sales; Backs Annual Sales OutlookMay 7, 2024 | globenewswire.comSandoz reports first quarter 2024 salesMay 2, 2024 | msn.comSandoz Group AG goes ex dividend tomorrowApril 30, 2024 | marketwatch.comSandoz Reaches Agreement With Amgen Resolving All Patent LitigationApril 30, 2024 | msn.comSandoz, Amgen reach agreement resolving patent litigation over biosimilarsApril 30, 2024 | globenewswire.comShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AGApril 30, 2024 | reuters.comSandoz reaches agreement with Amgen over patent disputeApril 30, 2024 | globenewswire.comSandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilarsApril 29, 2024 | msn.comAmgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelledApril 22, 2024 | markets.businessinsider.comSandoz : Pyzchiva Approved In Europe For Gastroenterology, Dermatology, And Rheumatology TreatmentsApril 22, 2024 | globenewswire.comSandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offeringMarch 21, 2024 | globenewswire.comSandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicinesMarch 14, 2024 | msn.comSandoz Group Non-GAAP EPS of $2.20, revenue of $9.65B; initiates FY24 and long-term outlookMarch 13, 2024 | theglobeandmail.comThe Cultivated B Introduces n!Biomachines: Fit-For-Purpose Bioreactors Designed to Easily and Affordably Scale Cellular AgricultureMarch 13, 2024 | globenewswire.comSandoz reports fourth quarter 2023 sales and full-year 2023 resultsMarch 6, 2024 | finanznachrichten.deSandoz Group: Sandoz receives FDA approval for first and only denosumab biosimilarsMarch 5, 2024 | globenewswire.comSandoz receives FDA approval for first and only denosumab biosimilarsMarch 5, 2024 | finanznachrichten.deSandoz Group: Sandoz announces nominations to the Board of Directors and leadership changeMarch 5, 2024 | finance.yahoo.comSandoz announces nominations to the Board of Directors and leadership changeMarch 5, 2024 | globenewswire.comSandoz announces nominations to the Board of Directors and leadership changeMarch 4, 2024 | globenewswire.comSandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US marketFebruary 29, 2024 | msn.comGeneric/Biosimilar Player Sandoz Settles US Price Fixing Case For $265MFebruary 29, 2024 | finanznachrichten.deSandoz Group: Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffsFebruary 29, 2024 | money.usnews.comSandoz Enters $265 Million Settlement Agreement in U.S. Price-Fixing CaseFebruary 29, 2024 | markets.businessinsider.comSandoz US Settles Antitrust Class Action Litigation With Direct Purchaser Class Plaintiffs February 29, 2024 | reuters.comSandoz enters $265 mln settlement agreement in U.S. price-fixing caseFebruary 29, 2024 | globenewswire.comSandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffsFebruary 20, 2024 | finance.yahoo.comSandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosisFebruary 1, 2024 | finance.yahoo.comSandoz announces changes in the Board of DirectorsJanuary 29, 2024 | marketbeat.comSandoz Group AG (OTCMKTS:SDZNY) Sees Large Increase in Short InterestSandoz Group AG (OTCMKTS:SDZNY - Get Free Report) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 2,622,500 shares, a growth of 21.8% from the December 31st total of 2,152,900 shares. Based on an average trading volume of 302,400 shares, the short-interest ratio is presently 8.7 days.January 22, 2024 | finanznachrichten.deSandoz Group: Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US marketJanuary 22, 2024 | finance.yahoo.comSandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US marketNovember 27, 2023 | finance.yahoo.comSandoz Canada announces first ever list of Top 100 most important medicines, from a clinical standpoint, for Canadian patientsNovember 21, 2023 | markets.businessinsider.comSandoz Unveils Hyrimoz Citrate-free High Concentration Formulation In EuropeNovember 21, 2023 | finance.yahoo.comSandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient careNovember 15, 2023 | wsj.comSandoz Group AG ADRNovember 11, 2023 | seekingalpha.comSandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028November 10, 2023 | finanznachrichten.deSandoz Group: Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in GermanyNovember 10, 2023 | finance.yahoo.comSandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in GermanyNovember 8, 2023 | finance.yahoo.comSandoz successfully issues EUR 2.0 billion inaugural EurobondsNovember 8, 2023 | finanznachrichten.deSandoz Group: Sandoz successfully issues EUR 2.0 billion inaugural EurobondsNovember 1, 2023 | morningstar.comSandoz Group AG ADR SDZNYOctober 29, 2023 | au.finance.yahoo.comSandoz Group AG (SDZNY)October 26, 2023 | finanznachrichten.deSandoz Group: Sandoz successfully issues CHF 750 million in inaugural bondsOctober 26, 2023 | finance.yahoo.comSandoz successfully issues CHF 750 million in inaugural bondsOctober 24, 2023 | markets.businessinsider.comSandoz 9-month Net Sales Up 6% In CC - Quick FactsOctober 24, 2023 | finance.yahoo.comSandoz reports year-to-date sales for the first nine months of 2023October 21, 2023 | ca.finance.yahoo.comSandoz Group AG (SDZ.SW) Get Sandoz Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SDZNY and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (Ad)Nanoviricides Technology Will Transform The Way Viruses & Their Variants Are Treated Worldwide And This Company Is At The Forefront! See how with its ongoing expansion and development SDZNY Media Mentions By Week SDZNY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SDZNY News Sentiment▼0.350.55▲Average Medical News Sentiment SDZNY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SDZNY Articles This Week▼31▲SDZNY Articles Average Week Get Sandoz Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SDZNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SGIOY News ERFSF News SSMXY News SKHHY News ACBFF News SBMFF News ORINY News APNHY News HKMPF News ZLDPF News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SDZNY) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sandoz Group AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
